Theranostics Market Research Report: Information By Therapeutic Area (Oncology, Cardiovascular Diseases, Neurological Disorders, Immunological Disorders and others), Technology [Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Sequencing, Others], End User (Hospitals and Clinics, Diagnostic Laboratories, Others) and Region - Forecast 2027
|ID: VPR/HC/1114||Publishing Year: January 2022||Pages: 110||Format:|
Theranostics Market Overview:
Theranostics is a relatively young branch of medicine that uses targeted medicines to perform specific targeted testing. These tests are mostly used to diagnose malignancies of various types. Patient-centered treatment with a more tailored and accurate approach is a major concern in medicines. The method combines diagnostic and therapeutic applications to create a single agent. End-users gain from the system because it improves drug delivery, diagnostics, and treatment response monitoring. Theranostics Market is predicted to increase significantly in the near future due to rising cancer occurrences and the growing need for cancer combination medicines.
- Thermo Fisher Scientific Inc.
- Beckman Coulter, Inc.
- Hoffmann-La Roche Ltd
- Focus Diagnostics
- Illumina, Inc.
- Agilent Technologies, Inc.
- Abbott Laboratories
- Myriad Genetics, Inc.
- Foundation Medicine, Inc.
- AmeriPath, Inc.
It's a brand-new branch of medicine that blends focused therapy with targeted diagnostic tests. The global increase in the development of novel companion diagnostic tests, the mounting adoption of companion diagnostic tests by end users, the increasing collaborations and partnerships by prominent market participants to develop innovative companion diagnostics, and the rising burden of chronic diseases are all factors driving the market forward. By the end of 2020, these diseases are expected to account for around three-quarters of all fatalities worldwide. On the contrary, during the forecast period of 2019 to 2025, the worldwide theranostics market size is expected to be limited by a lack of well defined laws for Theranostics Testing and insufficient reimbursement facilities in most nations.
Theranostics is divided into four categories: therapeutic area, technology, end user, and geography.
Oncology, cardiovascular illnesses, neurological disorders, immunological disorders, and others are the therapeutic areas in which the market has been classified. Breast cancer, colorectal cancer, lung cancer, cervical cancer, and other cancers are divided under the oncology category. Due to rising usage of theranostics in cancer disease to minimise multi-step procedures, reduce treatment delays, and improve patient care, the oncology sector dominated the market in 2018 and is likely to maintain its dominance during the forecast period.
The market has been segmented into polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), sequencing, and other technologies based on technology.
The market has been divided into hospitals and clinics, diagnostic laboratories, and others based on the end user.
The Global Theranostics Market is divided into four regions: North America, Europe, Asia-Pacific, and the Middle East and Africa. The Americas' theranostics market has been separated into North America and Latin America, with North America divided into the United States and Canada.
In the near future, the North American Theranostics Market is likely to increase significantly. Theranostics Market Growth is predicted to be fueled by rising cancer cases, more awareness, and expanded treatment choices. Rising disposable income, a big population, and more access to healthcare are projected to generate significant growth in the near future in the Asia Pacific Theranostics Industry. In Europe, as well, rising senior populations, technologically improved healthcare systems, and options such as universal care are likely to generate significant expansion.
Type Here for table of content.